Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 5.6% – Time to Sell?

Posted by Brian Himes on Sep 16th, 2026

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) shares were down 5.6% during mid-day trading on Wednesday . The stock traded as low as $50.36 and last traded at $50.3710. Approximately 732,748 shares traded hands during trading, a decline of 40% from the average daily volume of 1,219,042 shares. The stock had previously closed at $53.36.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ELVN. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Barclays assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 target price on the stock. Guggenheim decreased their price target on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. William Blair assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating for the company. Finally, The Goldman Sachs Group upped their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $75.00.

Get Our Latest Stock Report on Enliven Therapeutics

Enliven Therapeutics Price Performance

The company has a market cap of $3.69 billion, a PE ratio of -30.27 and a beta of 0.30. The business’s 50 day moving average is $56.53 and its 200-day moving average is $45.75.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other news, Director Lori Kunkel sold 10,000 shares of the company’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the transaction, the director directly owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. This represents a 19.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the transaction, the chief financial officer owned 40,036 shares in the company, valued at approximately $2,345,308.88. The trade was a 13.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 180,831 shares of company stock valued at $10,735,269 over the last quarter. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. First Light Asset Management LLC lifted its position in shares of Enliven Therapeutics by 574.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after buying an additional 1,158,883 shares during the last quarter. Tidal Investments LLC grew its position in shares of Enliven Therapeutics by 27.7% in the 2nd quarter. Tidal Investments LLC now owns 60,694 shares of the company’s stock valued at $3,080,000 after buying an additional 13,179 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in Enliven Therapeutics during the 2nd quarter worth $228,000. Engineers Gate Manager LP acquired a new stake in Enliven Therapeutics during the 2nd quarter worth $1,479,000. Finally, Squarepoint Ops LLC purchased a new stake in Enliven Therapeutics in the second quarter valued at $259,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.